Legal & General Group’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.07M | Sell |
188,650
-16,553
| -8% | -$357K | ﹤0.01% | 1604 |
|
|
2025
Q4 | $4.89M | Buy |
205,203
+26,806
| +15% | +$547K | ﹤0.01% | 1565 |
|
|
2025
Q3 | $2.43M | Sell |
178,397
-2,962
| -2% | -$30.8K | ﹤0.01% | 1898 |
|
|
2025
Q2 | $1.48M | Sell |
181,359
-4,200
| -2% | -$35.9K | ﹤0.01% | 2093 |
|
|
2025
Q1 | $1.46M | Buy |
185,559
+36,352
| +24% | +$421K | ﹤0.01% | 2041 |
|
|
2024
Q4 | $2.22M | Buy |
149,207
+2,233
| +2% | +$36.5K | ﹤0.01% | 1935 |
|
|
2024
Q3 | $2.25M | Sell |
146,974
-1,857
| -1% | -$29.3K | ﹤0.01% | 1917 |
|
|
2024
Q2 | $2.27M | Sell |
148,831
-1,421
| -0.9% | -$22.9K | ﹤0.01% | 1886 |
|
|
2024
Q1 | $2.84M | Buy |
150,252
+1,322
| +0.9% | +$22.9K | ﹤0.01% | 1778 |
|
|
2023
Q4 | $2.84M | Sell |
148,930
-1,265
| -0.8% | -$20.2K | ﹤0.01% | 1778 |
|
|
2023
Q3 | $2.7M | Buy |
150,195
+5,140
| +4% | +$103K | ﹤0.01% | 1760 |
|
|
2023
Q2 | $2.95M | Sell |
145,055
-3,785
| -3% | -$72.1K | ﹤0.01% | 1734 |
|
|
2023
Q1 | $2.71M | Sell |
148,840
-1,735
| -1% | -$33.2K | ﹤0.01% | 1738 |
|
|
2022
Q4 | $3.11M | Buy |
150,575
+2,024
| +1% | +$55.7K | ﹤0.01% | 1667 |
|
|
2022
Q3 | $3.89M | Buy |
148,551
+11,335
| +8% | +$300K | ﹤0.01% | 1493 |
|
|
2022
Q2 | $3.48M | Buy |
137,216
+100,107
| +270% | +$2.45M | ﹤0.01% | 1599 |
|
|
2022
Q1 | $1.17M | Buy |
37,109
+19,227
| +108% | +$644K | ﹤0.01% | 2191 |
|
|
2021
Q4 | $723K | Sell |
17,882
-482
| -3% | -$18.7K | ﹤0.01% | 2315 |
|
|
2021
Q3 | $640K | Buy |
18,364
+8,095
| +79% | +$252K | ﹤0.01% | 2354 |
|
|
2021
Q2 | $281K | Sell |
10,269
-1,237
| -11% | -$35.3K | ﹤0.01% | 2458 |
|
|
2021
Q1 | $323K | Buy |
11,506
+445
| +4% | +$15.5K | ﹤0.01% | 2372 |
|
|
2020
Q4 | $287K | Sell |
11,061
-80
| -0.7% | -$1.94K | ﹤0.01% | 2355 |
|
|
2020
Q3 | $191K | Sell |
11,141
-320
| -3% | -$7.15K | ﹤0.01% | 2366 |
|
|
2020
Q2 | $284K | Buy |
11,461
+6,476
| +130% | +$175K | ﹤0.01% | 2287 |
|
|
2020
Q1 | $69K | Sell |
4,985
-1,685
| -25% | -$21K | ﹤0.01% | 2510 |
|
|
2019
Q4 | $68K | Hold |
6,670
| – | – | ﹤0.01% | 2711 |
|
|
2019
Q3 | $61K | Buy |
6,670
+852
| +15% | +$6.85K | ﹤0.01% | 2669 |
|
|
2019
Q2 | $47K | Hold |
5,818
| – | – | ﹤0.01% | 2801 |
|
|
2019
Q1 | $73K | Hold |
5,818
| – | – | ﹤0.01% | 2591 |
|
|
2018
Q4 | $62K | Buy |
5,818
+4,404
| +311% | +$51.4K | ﹤0.01% | 2614 |
|
|
2018
Q3 | $20K | Buy |
1,414
+651
| +85% | +$8.3K | ﹤0.01% | 3207 |
|
|
2018
Q2 | $9K | Buy |
+763
| New | +$12K | ﹤0.01% | 3310 |
|
Other funds holding RCUS
GS
SCM
VPM
VCM
WP
SL
Legal & General Group's RCUS Position: Q1 2026 in Review
Legal & General Group reduced its Arcus Biosciences (RCUS) stake by 8.1% in Q1 2026, selling an estimated $357K and leaving 188,650 shares worth $4.07M. The position accounts for ﹤0.01% of the portfolio, ranked #1604.
Legal & General Group first reported a position in RCUS in Q2 2018 and has held it in 32 quarters since. The position peaked at $4.89M in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.
- Legal & General Group held 188,650 shares of Arcus Biosciences worth $4.07M as of Q1 2026.
- Legal & General Group sold 16,553 Arcus Biosciences shares in Q1 2026, an estimated $357K.
- Arcus Biosciences made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #1604 holding.
- Legal & General Group first reported a position in Arcus Biosciences in Q2 2018 and has held it in 32 quarters since.
- Legal & General Group's Arcus Biosciences position peaked at $4.89M in Q4 2025.
- 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.
Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.